Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, +20

Annals of Oncology

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, +117

The Lancet Haematology

Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor +4

Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA

Yoko Otake, Sridharan Soundararajan, Tapas K. Sengupta, +6

Blood

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse, +15

Cancer

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, +20

Clinical Cancer Research

Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

Pierre Chabot, Te‐Chun Hsia, Jeong‐Seon Ryu, +10

Journal of Neuro-Oncology

Brain MetastasesRadiation TherapyMedicinePlacebo-controlled StudyCancer Treatment +6

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

Suresh S. Ramalingam, Normand Blais, Julien Mazières, +15

Clinical Cancer Research

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, +179

Annals of Oncology

Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study +5

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, +13

Clinical Cancer Research

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Greg Andrew Durm, Sandra K. Althouse, Ahad A. Sadiq, +11

Journal of Clinical Oncology

Phase Ii TrialMedicineMetronomic TherapyPharmacologyClinical Trials +12